ARWR

SEC source: 0001209191-20-038767 · doc4.xml · nonDerivative · entry 3

De Backer Marianne · CIK 0001797819 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,000

SEC source: 0001209191-20-038767 · doc4.xml · nonDerivative · entry 2

De Backer Marianne · CIK 0001797819 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,500

SEC source: 0001209191-20-013488 · doc4.xml · derivative · entry 10

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,671

Underlying: Common Stock · 10,834 shares

Expires 2026-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Represents the first vesting date. Option vested over four years from date of grant.

SEC source: 0001209191-20-013488 · doc4.xml · derivative · entry 9

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,505

Underlying: Common Stock · 12,116 shares

Expires 2025-03-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Represents the first vesting date. Option vested over four years from date of grant.

SEC source: 0001209191-20-013488 · doc4.xml · derivative · entry 8

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,621

Underlying: Common Stock · 6,495 shares

Expires 2024-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Represents the first vesting date. Option vested over four years from date of grant.

SEC source: 0001209191-20-013488 · doc4.xml · derivative · entry 7

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,116

Underlying: Common Stock · 2,000 shares

Expires 2022-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Represents the first vesting date. Option vested over four years from date of grant.

SEC source: 0001209191-20-013488 · doc4.xml · derivative · entry 6

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,116

Underlying: Common Stock · 12,000 shares

Expires 2020-08-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Represents the first vesting date. Option vested over four years from date of grant.

SEC source: 0001209191-20-013488 · doc4.xml · nonDerivative · entry 5

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 427,668

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-013488 · doc4.xml · nonDerivative · entry 4

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 416,834

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-013488 · doc4.xml · nonDerivative · entry 3

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 404,718

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-013488 · doc4.xml · nonDerivative · entry 2

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 398,223

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-013488 · doc4.xml · nonDerivative · entry 1

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 396,223

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-010599 · doc4.xml · nonDerivative · entry 1

Ferrari Mauro · CIK 0001506045 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,971

F1 · shares: When the Board determined its 2019 compensation, Dr. Ferrari's equity compensation was limited by the policies of his employer. During 2019, Dr. Ferrari became no longer subject to these limitations. This award makes up the difference between the number of shares Dr. Ferrari was originally awarded in January 2019 and the number of shares awarded to other directors of the Company's Board in January 2019.

SEC source: 0001209191-20-004722 · doc4.xml · derivative · entry 8

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,116

Underlying: Common Stock · 33,351 shares

Expires 2022-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant.

SEC source: 0001209191-20-004722 · doc4.xml · nonDerivative · entry 7

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 384,223

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F7 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.70 to $52.39, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-20-004722 · doc4.xml · nonDerivative · entry 6

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 387,673

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F6 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.67 to $51.54, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-20-004722 · doc4.xml · nonDerivative · entry 5

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 398,353

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F5 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.64 to $50.41, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-20-004722 · doc4.xml · nonDerivative · entry 4

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 401,153

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F4 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.62 to $49.62, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-20-004722 · doc4.xml · nonDerivative · entry 3

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 411,707

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.60 to $48.60, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-20-004722 · doc4.xml · nonDerivative · entry 2

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 418,139

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.58 to $47.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-20-004722 · doc4.xml · nonDerivative · entry 1

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 424,536

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-038767 · doc4.xml · nonDerivative · entry 1

De Backer Marianne · CIK 0001797819 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,000

SEC source: 0001209191-20-002615 · doc4.xml · nonDerivative · entry 3

O'Brien Patrick · CIK 0001627183 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 258,375

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units

SEC source: 0001209191-20-002615 · doc4.xml · nonDerivative · entry 2

O'Brien Patrick · CIK 0001627183 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 258,475

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units

F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.93 to $60.92, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-20-002615 · doc4.xml · nonDerivative · entry 1

O'Brien Patrick · CIK 0001627183 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 267,406

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units

F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.92 to $59.92, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-20-002617 · doc4.xml · nonDerivative · entry 3

GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 858,993

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.

F4 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.92 to $61.04, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-20-002617 · doc4.xml · nonDerivative · entry 2

GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 860,293

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.

F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.91 to $60.91, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-20-002617 · doc4.xml · nonDerivative · entry 1

GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 882,759

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.

F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.90 to $59.90, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-20-002613 · doc4.xml · nonDerivative · entry 3

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 391,185

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.

F4 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.95 to $61.04, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-20-002613 · doc4.xml · nonDerivative · entry 2

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 391,685

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.

F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.93 to $60.92, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-20-002613 · doc4.xml · nonDerivative · entry 1

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 403,592

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.

F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.92 to $59.92, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-20-001333 · doc4.xml · nonDerivative · entry 1

GIVEN DOUGLAS B · CIK 0001156207 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,925

F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date.

SEC source: 0001209191-20-001359 · doc4.xml · nonDerivative · entry 1

Waddill William D. · CIK 0001553338 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,000

F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date.

SEC source: 0001209191-20-001372 · doc4.xml · nonDerivative · entry 1

De Backer Marianne · CIK 0001797819 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date.

SEC source: 0001209191-20-001366 · doc4.xml · nonDerivative · entry 1

PERRY MICHAEL S · CIK 0001250379 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,000

F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date.

SEC source: 0001209191-20-001356 · doc4.xml · nonDerivative · entry 1

GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 894,606

F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments.

SEC source: 0001209191-20-001343 · doc4.xml · nonDerivative · entry 1

Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 411,185

F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments.

SEC source: 0001209191-20-001353 · doc4.xml · nonDerivative · entry 1

O'Brien Patrick · CIK 0001627183 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 273,000

F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments.

SEC source: 0001209191-20-001349 · doc4.xml · nonDerivative · entry 1

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,705,237

F1 · shares: Represents the maximum number of shares underlying a restricted stock unit that may be earned based on the achievement of nine predetermined performance goals related to the advancement of the Company's clinical and preclinical programs and business development that must be achieved within five years. If the performance goals are not met within the required time periods, the award will be forfeited in part or in whole.

F2 · balance_after: Includes a total of 1,300,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole.

SEC source: 0001209191-20-001338 · doc4.xml · nonDerivative · entry 1

Ferrari Mauro · CIK 0001506045 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,400

F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date.

SEC source: 0001209191-19-062035 · doc4.xml · nonDerivative · entry 1

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,805,237

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.

F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.17 to $63.65, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F3 · balance_after: Includes a total of 400,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole.

SEC source: 0001209191-19-060507 · doc4.xml · nonDerivative · entry 8

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,888,570

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.

F9 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.03 to $68.47, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F10 · balance_after: Includes a total of 566,667 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole.

SEC source: 0001209191-19-060507 · doc4.xml · nonDerivative · entry 7

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,891,963

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.

F8 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.01 to $67.99, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-19-060507 · doc4.xml · nonDerivative · entry 6

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,917,375

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.

F7 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.01 to $67.00, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-19-060507 · doc4.xml · nonDerivative · entry 5

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,962,952

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.

F6 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.61 to $66.00, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-19-060507 · doc4.xml · nonDerivative · entry 4

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,971,903

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.

F5 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.01 to $69.95, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-19-060507 · doc4.xml · nonDerivative · entry 3

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,980,282

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.

F4 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.02 to $69.00, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-19-060507 · doc4.xml · nonDerivative · entry 2

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,990,625

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.

F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.01 to $67.99, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-19-060507 · doc4.xml · nonDerivative · entry 1

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,048,684

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.

F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.00 to $67.00, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0001209191-19-059171 · doc4.xml · nonDerivative · entry 9

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,071,903

F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F10 · balance_after: Includes a total of 933,333 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole.